Keytruda – Health

FDA Approves Merck’s Keytruda (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation

Print this page KENILWORTH, N.J.–(BUSINESS WIRE)– Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by… Read More »

Bristol arms itself for kidney-cancer fight as Keytruda threatens Opdivo’s share

Bristol-Myers Squibb investors have been dreading the arrival of Merck’s Keytruda in kidney cancer, one of Opdivo’s key growth areas. Bristol’s execs? Not so much. The company has been preparing for the launch of I-O-plus-TKI regimens—such as the marriage of Keytruda and Pfizer’s Inlyta that won FDA approval Monday, or the Bavencio-Inlyta duo that Pfizer… Read More »